These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 27643871)

  • 41. Quality of life in patients with transfusion-dependent thalassemia after hematopoietic SCT.
    Cheuk DK; Mok AS; Lee AC; Chiang AK; Ha SY; Lau YL; Chan GC
    Bone Marrow Transplant; 2008 Sep; 42(5):319-27. PubMed ID: 18560410
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan Society for Hematopoietic Cell Transplantation Working Party.
    Kataoka I; Kami M; Takahashi S; Kodera Y; Miyawaki S; Hirabayashi N; Okamoto S; Matsumoto N; Miyazaki Y; Morishita Y; Asai O; Maruta A; Yoshida T; Imamura M; Hamajima N; Matsuo K; Harada M; Mineishi S;
    Bone Marrow Transplant; 2004 Oct; 34(8):711-9. PubMed ID: 15361916
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.
    Gaziev J; Sodani P; Polchi P; Andreani M; Lucarelli G
    Ann N Y Acad Sci; 2005; 1054():196-205. PubMed ID: 16339666
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry.
    Michallet M; Sobh M; Milligan D; Morisset S; Niederwieser D; Koza V; Ruutu T; Russell NH; Verdonck L; Dhedin N; Vitek A; Boogaerts M; Vindelov L; Finke J; Dubois V; van Biezen A; Brand R; de Witte T; Dreger P;
    Leukemia; 2010 Oct; 24(10):1725-31. PubMed ID: 20703257
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Graft versus lymphoma effect after early relapse following reduced-intensity sibling allogeneic stem cell transplantation for relapsed cytotoxic variant of mycosis fungoides.
    Gabriel IH; Olavarria E; Jones RR; Whittaker S; Chaidos A; Apperley JF
    Bone Marrow Transplant; 2007 Aug; 40(4):401-3. PubMed ID: 17589536
    [No Abstract]   [Full Text] [Related]  

  • 46. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
    Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
    Soni S; Gross TG; Rangarajan H; Baker KS; Sturm M; Rhodes M
    Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term results after transplantation of CD34+ selected (CellPro) versus unselected peripheral blood progenitor cells (PBPC) from related allogeneic donors.
    Kopp HG; Wirths S; Faul C; Bethge W; Scheding S; Brugger W; Kanz L; Vogel W
    J Cancer Res Clin Oncol; 2010 Dec; 136(12):1921-7. PubMed ID: 20217128
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?
    Mehta J; Gordon LI; Tallman MS; Winter JN; Evens AM; Frankfurt O; Williams SF; Grinblatt D; Kaminer L; Meagher R; Singhal S
    Bone Marrow Transplant; 2006 Jul; 38(2):95-100. PubMed ID: 16751789
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HLA-matched family hematopoetic stem cell transplantation in children with beta thalassemia major: the experience of the Turkish Pediatric Bone Marrow Transplantation Group.
    Yesilipek MA; Ertem M; Cetin M; Öniz H; Kansoy S; Tanyeli A; Anak S; Kurekci E; Hazar V
    Pediatr Transplant; 2012 Dec; 16(8):846-51. PubMed ID: 22931438
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hematopoietic stem cell transplantation in acute promyelocytic leukemia, experience in Iran.
    Alimoghaddam K; Ghavamzadeh A; Jahani M; Jalali A; Jorjani H; Iravani M; Hamidieh AA; Mousavi A; Bahar B; Behfar M; Derakhshandeh R; Rostami S
    Arch Iran Med; 2011 Sep; 14(5):332-4. PubMed ID: 21888457
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimal Outcomes in Young Class 3 Patients With Thalassemia Undergoing HLA-Identical Sibling Bone Marrow Transplantation.
    Gaziev J; Isgrò A; Sodani P; Marziali M; Paciaroni K; Gallucci C; De Angelis G; Andreani M; Testi M; Alfieri C; Ribersani M; Galluccio T; Battarra MR; Morrone A; Lucarelli G
    Transplantation; 2016 Apr; 100(4):925-32. PubMed ID: 26457600
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcome of allogeneic haematopoietic stem cell transplantation in aplastic anaemia.
    Ahmed P; Chaudhry QU; Raza S; Mahmood SK; Satti TM; Anwar M; Altaf C; Shahbaz N; Satti HS
    J Coll Physicians Surg Pak; 2012 Sep; 22(9):553-9. PubMed ID: 22980607
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Haploidentical and Matched Sibling Donor Hematopoietic Cell Transplantation for Patients with HLA-Homozygous Haplotypes.
    Kanda J; Ikegame K; Fuji S; Kurokawa M; Kanamori H; Fukuda T; Ohashi K; Ishikawa J; Ogawa H; Inoue M; Ichinohe T; Atsuta Y; Kanda Y;
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):2031-2037. PubMed ID: 27492794
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Having a sibling as donor: patients' experiences immediately before allogeneic hematopoietic stem cell transplantation.
    Kisch A; Bolmsjö I; Lenhoff S; Bengtsson M
    Eur J Oncol Nurs; 2014 Aug; 18(4):436-42. PubMed ID: 24721180
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity.
    Cohen S; Kiss T; Lachance S; Roy DC; Sauvageau G; Busque L; Ahmad I; Roy J
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):951-7. PubMed ID: 22155507
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond.
    Hwang YY; Mohty M; Chim CS
    Hematology; 2015 Mar; 20(2):61-71. PubMed ID: 24993587
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical outcome after sex-mismatched allogeneic stem cell transplantation from human lymphocyte antigen-identical sibling donors: influence of stem cell source.
    Gallardo D; Pérez-García A; de la Cámara R; Iriondo A; Jiménez-Velasco A; Torres A; Brunet S; Urbano-Ispizúa A; Vallejo C; Encuentra M; Caballero D; Espigado I; Serrano D; Barrenetxea C; Ribera JM; de la Rubia J;
    Leukemia; 2006 Aug; 20(8):1461-4. PubMed ID: 16728983
    [No Abstract]   [Full Text] [Related]  

  • 59. Is ABO mismatch another risk factor for allogeneic hematopoietic stem cell transplantation in pediatric thalassemic patients?
    Atay D; Erbey F; Akcay A; Ozturk G
    Pediatr Transplant; 2015 Sep; 19(6):645-51. PubMed ID: 26156679
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regarding chronic graft-versus-host disease in children and adolescents with thalassemia after hematopoietic stem cell transplantation.
    Janowiak-Majeranowska A; Majeranowski A
    Int J Hematol; 2021 Jul; 114(1):147-148. PubMed ID: 33704664
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.